Mizuho Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $22

Mizuho analyst Graig Suvannavejh has initiated coverage on Regenxbio (NASDAQ: RGNX) with an Outperform rating. The firm has set a price target of $22 for the company's stock.